Sanggu Kim¹, Seongmo Yang¹, Soochong Kim^1,2,*

BIOCELL, Vol.49, No.12, pp. 2335-2364, 2025, DOI:10.32604/biocell.2025.072418 - 24 December 2025

Abstract Regenerative medicine has attracted increasing attention across diverse organs, including the skin, musculoskeletal tissues, eye, and nervous system, where structural repair is limited. Among these, skin wound care is particularly urgent and challenging because diabetic ulcers, pressure injuries, and severe burns often resist standard dressings, debridement, and revascularization, resulting in infection, amputation, and high costs. Platelet-rich plasma (PRP) has gained value because platelets release coordinated growth factors and cytokines (e.g., platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, epidermal growth factor, fibroblast growth factor, and insulin-like growth factor-1) that modulate hemostasis, inflammation, angiogenesis,… More >

Chenglu Lu^1,#, Huiting Zhang^2,#, Ujjal K. Bhawal^3,4, Lei Wang¹, Jingwu Li¹, Pangzhou Chen^5,*, Lewei Zhu^6,*

Oncology Research, Vol.33, No.12, pp. 3657-3678, 2025, DOI:10.32604/or.2025.069703 - 27 November 2025

Abstract The tumor microenvironment (TME) is a complex network composed of non-tumor cells, extracellular matrix, blood vessels, and various molecular signals that surround and profoundly influence tumor progression. As one of the key immune effector cells within the TME, mast cells (MCs) exhibit functional complexity, and their specific roles remain widely debated. Depending on the cancer type, spatial distribution, and interactions with other TME components, MCs can demonstrate dual regulatory capabilities—either promoting or inhibiting tumor growth. This characteristic has made them an important focus in current tumor immunology research. This review aims to systematically review the More >

MD. MAHMUDUL HASAN^1,2, SHAH MD. WASIN^2,3, MISHU RAHMAN^2,4, EVA AZME^1,2, MD. SAQLINE MOSTAQ⁵, MD. MAHEDI HASAN NAHID⁶, NOR MOHAMMAD⁷, FARJANA AFRIN TANJUM⁸, MD. ANAMUL HAQUE⁵, MD ASHIQ MAHMUD^5,*, MOHAMMAD NURUL AMIN^5,*

Oncology Research, Vol.33, No.7, pp. 1611-1632, 2025, DOI:10.32604/or.2025.062778 - 26 June 2025

Abstract Background: Breast cancer still stands to be the foremost contributor to cancer-related incidence and mortality in women globally accounting for about 14% of all female cancer-related deaths worldwide. This research seeks to illustrate the mechanisms and clinical findings of natural products against breast cancer treatment. Methodology: Required data for this review article was retrieved employing several readily obtainable search databases, including Web of Science^® (Thomson Reuters, USA), PubMed^® (U.S. National Library of Medicine, USA), and SciVerse Scopus^® (Elsevier Properties S.A., USA), taking into consideration certain search terms like “breast cancer,” “natural products against breast cancer,” and “Clinically… More > Graphic Abstract

Ayda Baghery Saghchy Khorasani¹, Mahda Delshad², Mohammad-Javad Sanaei^2,3, Atieh Pourbagheri-Sigaroodi², Ali Pirsalehi⁴, Davood Bashash^2,*

BIOCELL, Vol.49, No.4, pp. 539-562, 2025, DOI:10.32604/biocell.2025.059970 - 30 April 2025

Abstract Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third leading cause of cancer-related mortality globally. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway is critically involved in HCC pathogenesis, stimulating uncontrolled cell proliferation, survival, and tumor progression. The overactivation of this pathway is strongly linked to poor prognosis, making it a crucial target for therapeutic intervention. The oncogenic roles of PI3K/AKT/mTOR components in HCC have been highlighted, noting that class I PI3K deregulation, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) upregulation, and mTOR overexpression could be associated… More >

Mukul Mishra¹, Deeba Khan², Sehbanul Islam^1,*

BIOCELL, Vol.49, No.1, pp. 127-147, 2025, DOI:10.32604/biocell.2025.058038 - 24 January 2025

Abstract The COVID-19 pandemic, caused by the newly emerged coronavirus SARS-CoV-2, has resulted in unprecedented global health challenges, including millions of infections and deaths. While the direct effects of the virus are critical, the interplay between SARS-CoV-2 and cellular host factors significantly impacts the replication cycle of the virus and the clinical severity of COVID-19. This review provides a comprehensive analysis of host-pathogen interactions, focusing on the functional roles and regulatory mechanisms of SARS-CoV-2 viral proteins. We systematically review the literature to detail how SARS-CoV-2 engages with host cellular machinery, with a specific emphasis on their More >

WEITAO ZHENG¹, DONG JIANG², SONGEN CHEN¹, MEILING WU¹, BAOQI YAN², JIAHUI ZHAI², YUNQIANG SHI², BIN XIE¹, XINGWANG XIE², KANGHONG HU^1,*, WENXUE MA^3,*

Oncology Research, Vol.32, No.12, pp. 1837-1850, 2024, DOI:10.32604/or.2024.056565 - 13 November 2024

Abstract Objectives: The Kirsten rat sarcoma virus (KRAS) G12D oncogenic mutation poses a significant challenge in treating solid tumors due to the lack of specific and effective therapeutic interventions. This study aims to explore innovative approaches in T cell receptor (TCR) engineering and characterization to target the KRAS G12D_7-16 mutation, providing potential strategies for overcoming this therapeutic challenge. Methods: In this innovative study, we engineered and characterized two T cell receptors (TCRs), KDA11-01 and KDA11-02 with high affinity for the KRAS G12D_7-16 mutation. These TCRs were isolated from tumor-infiltrating lymphocytes (TILs) derived from tumor tissues of patients More >

JINXIA CHEN^1,2,3,#, SULI DAI^1,2,#, GENG ZHANG^4,5, SISI WEI^1,2, XUETAO ZHAO³, YANG ZHENG^1,2, YAOJIE WANG^1,2, XIAOHAN WANG^1,2, YUNJIANG LIU^4,5,*, LIANMEI ZHAO^1,2,*

Oncology Research, Vol.32, No.11, pp. 1791-1802, 2024, DOI:10.32604/or.2024.049348 - 16 October 2024

Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear. Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC.… More > Graphic Abstract

RUIFANG LI¹, XINRONG NAN^2,*, MING LI^3,*, OMAR RAHHAL³

Oncology Research, Vol.32, No.8, pp. 1323-1334, 2024, DOI:10.32604/or.2024.046965 - 17 July 2024

Abstract Background: Fibroblast activation protein (FAP), a cell surface serine protease, plays roles in tumor invasion and immune regulation. However, there is currently no pan-cancer analysis of FAP. Objective: We aimed to assess the pan-cancer expression profile of FAP, its molecular function, and its potential role in head and neck squamous cell carcinoma (HNSC). Methods: We analyzed gene expression, survival status, immune infiltration, and molecular functional pathways of FAP in The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) tumors. Furthermore, to elucidate the role of FAP in HNSC, we performed proliferation, migration, and invasion assays… More >

QINGPAN BU, PING LI, YUNFEI XIA, XINPEI WEI, KAI SONG^*

BIOCELL, Vol.47, No.11, pp. 2535-2546, 2023, DOI:10.32604/biocell.2023.030781 - 27 November 2023

Abstract Mannose, a different isomer of the hydroxyl group at the C-2 position of glucose, shares the same transport carrier protein with glucose to enter cells and participate in the regulation of glucose metabolism. It affects cell growth, differentiation, and function and plays an active role in tumor immunity and inflammatory processes. This paper provides theoretical support for expanding the clinical applications of mannose by exploring its constitution, metabolic pathways, and role in regulating immune cell function and treating immunology-related diseases. More > Graphic Abstract

Mohammad Reza Haghshenas¹, Mina Roshan Zamir¹, Mahboubeh Sadeghi¹, Mohammad Javad Fattahi¹, Kimia Mirshekari¹, Abbas Ghaderi^1,2,*

European Cytokine Network, Vol.33, No.3, pp. 54-69, 2022, DOI:10.1684/ecn.2022.0480

Abstract Interleukin-38 (IL-38) is the most recent member of the IL-1 family that acts as a natural inflammatory inhibitor by binding to cognate receptors, particularly the IL-36 receptor. In vitro, animal and human studies on autoimmune, metabolic, cardiovascular and allergic diseases, as well sepsis and respiratory viral infections, have shown that IL-38 exerts an anti-inflammatory activity by modulating the generation and function of inflammatory cytokines (e.g. IL-6, IL-8, IL-17 and IL-36) and regulating dendritic cells, M2 macrophages and regulatory T cells (Tregs). Accordingly, IL-38 may possess therapeutic potential for these types of diseases. IL-38 down-regulates CCR3+… More >